Washington Trust’s Moderna MRNA Stock Holding History

Washington Trust’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$225K	Buy	+4,428	New	+$207K	0.01%	267
2025 Q2	–	Sell	-4,628	Closed	-$131K	–	538
2025 Q1	$131K	Sell	4,628 -300	-6%	-$10.6K	0.01%	293
2024 Q4	$205K	Sell	4,928 -121	-2%	-$5.78K	0.01%	262
2024 Q3	$337K	Sell	5,049 -2,512	-33%	-$231K	0.01%	236
2024 Q2	$898K	Hold	7,561	–	–	0.03%	159
2024 Q1	$806K	Hold	7,561	–	–	0.03%	162
2023 Q4	$752K	Hold	7,561	–	–	0.03%	166
2023 Q3	$781K	Hold	7,561	–	–	0.03%	146
2023 Q2	$919K	Hold	7,561	–	–	0.04%	142
2023 Q1	$1.16M	Sell	7,561 -22	-0.3%	-$3.63K	0.05%	132
2022 Q4	$1.36M	Hold	7,583	–	–	0.06%	125
2022 Q3	$897K	Buy	7,583 +121	+2%	+$18.4K	0.05%	136
2022 Q2	$1.07M	Hold	7,462	–	–	0.05%	129
2022 Q1	$1.28M	Hold	7,462	–	–	0.05%	129
2021 Q4	$1.9M	Sell	7,462 -788	-10%	-$230K	0.07%	118
2021 Q3	$3.17M	Sell	8,250 -721	-8%	-$266K	0.09%	137
2021 Q2	$2.11M	Buy	8,971 +312	+4%	+$55.8K	0.06%	150
2021 Q1	$1.13M	Hold	8,659	–	–	0.03%	169
2020 Q4	$905K	Buy	8,659 +8,624	+24,640%	+$872K	0.03%	177
2020 Q3	$2K	Buy	+35	New	+$2.44K	﹤0.01%	880

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Washington Trust's MRNA Position: Q1 2026 in Review

Washington Trust opened a new position in Moderna (MRNA) in Q1 2026: 4,428 shares worth $225K. The stake represents 0.01% of the portfolio and ranks #267 among its holdings. This is a return to the name: Washington Trust previously reported a position in MRNA as recently as Q1 2025.

Washington Trust first reported a position in MRNA in Q3 2020 and has held it in 20 quarters since. The position peaked at $3.17M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Washington Trust held 4,428 shares of Moderna worth $225K as of Q1 2026.
Moderna was a new Washington Trust position in Q1 2026.
Moderna made up 0.01% of Washington Trust's portfolio in Q1 2026, its #267 holding.
Washington Trust first reported a position in Moderna in Q3 2020 and has held it in 20 quarters since.
Washington Trust's Moderna position peaked at $3.17M in Q3 2021.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Washington Trust's 13F filing for Q1 2026, filed 6 Apr 2026.